There are 26 approved antiretroviral drugs available in 2012 in 6 mechanistic classes: reverse transcripatase inhibitors (both nucleosides and non-nucleosides), protease inhibitors, entry inhibitors (both fusion inhibitors and CCR5 receptor antagonists), and integrase inhibitors. Current antiretroviral therapy combinations dramatically decrease HIV-related morbidity and mortality. However, despite these advances, some current antiretroviral regimens may be inconvenient, toxic, and/or have suboptimal antiretroviral activity, particularly against drug-resistant viruses. Thus, newer compounds are needed that improve convenience and tolerability, reduce toxicity, and improve antiretroviral activity, particularly against drug-resistant viruses. Additionally, new drugs may better penetrate tissue reservoirs (e.g. genital tract, central nervous system), exploit new targets with new mechanisms of action, or be administered in new formulations.
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There are a number of HIV investigational drugs in development currently. These include a new pharmacokinetic "boosting" agent, cobicistat (GS-9350) and newer antiretroviral agents in a number of classes, including new nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, and integrase inhibitors. Of those in the pipeline, a few compounds are in advanced stages of development: the nucleoside analogue GS-7340, a pro-drug of tenofovir (phase 2); and the integrase inhibitors, elvitegravir (phase 3 completed) and dolutegravir (phase 3). In addition, there are drugs with new mechanisms of action in development, including the CD4 attachment inhibitor, BMS-663068 (phase 2), and the CCR5 antagonist, cenicriviroc (phase 2).
Probably the greatest need in the HIV clinic today is compounds that have activity against multidrug-resistant viral strains. Another important need is alternative onepill, once-daily formulations for both initial and subsequent regimens. However, the clinical use of these newer agents will depend on the results of phase 3 clinical trials, and the timeline for development and availability. 
